Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Arthritis, Gouty Clinical Trial

Official title:
A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout

Status Completed

Clinical Trial Summary

This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Arthritis, Gouty

Clinical Trial Details

NCT number	NCT00663169
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	April 2008
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05119686` - Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 2
Recruiting	`NCT06439602` - Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 3
Completed	`NCT00549549` - Celebrex In Acute Gouty Arthritis Study	Phase 3
Active, not recruiting	`NCT05253833` - Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout	Phase 2
Not yet recruiting	`NCT05966701` - The MAD Study of SSGJ-613 in Healthy Subjects	Phase 1